Profile data is unavailable for this security.
About the company
ASP Isotopes Inc. is a pre-commercial stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100 and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
- Revenue in USD (TTM)433.03k
- Net income in USD-16.29m
- Incorporated2021
- Employees76.00
- LocationASP Isotopes Inc1101 Pennsylvania Avenue Nw, Suite 300WASHINGTON 20004United StatesUSA
- Phone+1 (202) 756-2245
- Fax+1 (302) 636-5454
- Websitehttps://aspisotopes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | 0.00 | -125.55m | 219.72m | 128.00 | -- | 1.04 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Compass Therapeutics Inc. | 0.00 | -45.44m | 220.14m | 32.00 | -- | 1.40 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 223.05m | 40.00 | -- | 2.85 | -- | 471.04 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 223.75m | -- | -- | 11.58 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Agenus Inc | 161.42m | -239.61m | 228.05m | 389.00 | -- | -- | -- | 1.41 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| ASP Isotopes Inc | 433.03k | -16.29m | 233.97m | 76.00 | -- | 13.57 | -- | 540.30 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 33.90m | -92.95m | 234.65m | 116.00 | -- | -- | -- | 6.92 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 234.69m | 10.00 | -- | 2.07 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 236.83m | 100.00 | -- | 8.53 | -- | 2.82 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 240.00m | 9.00 | -- | 2.12 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 241.04m | 167.00 | -- | -- | -- | 1.29 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.40 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 82.75 | 69.13 | -22.98 | -82.25 | 1.31 | -5.00 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 243.22m | 249.00 | -- | -- | -- | 0.8057 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Generation Bio Co | 9.96m | -169.06m | 243.50m | 174.00 | -- | 1.84 | -- | 24.44 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 244.34m | 51.00 | -- | 1.33 | -- | 15.13 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 246.75m | 274.00 | -- | 1.19 | -- | 3.47 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Data as of May 17 2024. Currency figures normalised to ASP Isotopes Inc's reporting currency: US Dollar USD
5.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.01m | 2.07% |
| Millennium Management LLCas of 31 Mar 2024 | 356.42k | 0.73% |
| Geode Capital Management LLCas of 31 Mar 2024 | 304.52k | 0.62% |
| GSA Capital Partners LLPas of 31 Mar 2024 | 254.82k | 0.52% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 220.02k | 0.45% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 162.60k | 0.33% |
| Rathbones Investment Management Ltd.as of 31 Mar 2024 | 153.67k | 0.31% |
| Jane Street Capital LLCas of 31 Mar 2024 | 141.33k | 0.29% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 116.10k | 0.24% |
| HRT Financial LLCas of 31 Mar 2024 | 115.23k | 0.24% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
